India, Sept. 29 -- image credit- freepik

Delhi-based Akums Drugs & Pharmaceuticals, a Contract Development and Manufacturing Organization (CDMO), has received DCGI approval for Colchicine 0.5 mg Tablets, marking a significant addition to its cardiovascular and preventive cardiology portfolio.

The approval represents a first-time-in-India regulatory milestone for this application and reinforces Akums' focus on differentiated therapies addressing evolving healthcare needs.The approval comes at a time when India's pharmaceutical market continues to witness strong growth, particularly across chronic therapies. According to Pharmarack, the Indian Pharmaceutical Market (IPM) grew 10.7% year-on-year in August 2026 to Rs 23,272 crore.

Chronic ...